These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

644 related articles for article (PubMed ID: 22211105)

  • 1. EZH2 methyltransferase and H3K27 methylation in breast cancer.
    Yoo KH; Hennighausen L
    Int J Biol Sci; 2012; 8(1):59-65. PubMed ID: 22211105
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A model for transmission of the H3K27me3 epigenetic mark.
    Hansen KH; Bracken AP; Pasini D; Dietrich N; Gehani SS; Monrad A; Rappsilber J; Lerdrup M; Helin K
    Nat Cell Biol; 2008 Nov; 10(11):1291-300. PubMed ID: 18931660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phosphorylation of EZH2 by CDK1 and CDK2: a possible regulatory mechanism of transmission of the H3K27me3 epigenetic mark through cell divisions.
    Zeng X; Chen S; Huang H
    Cell Cycle; 2011 Feb; 10(4):579-83. PubMed ID: 21278485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FOXC1, a target of polycomb, inhibits metastasis of breast cancer cells.
    Du J; Li L; Ou Z; Kong C; Zhang Y; Dong Z; Zhu S; Jiang H; Shao Z; Huang B; Lu J
    Breast Cancer Res Treat; 2012 Jan; 131(1):65-73. PubMed ID: 21465172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Repression of E-cadherin by the polycomb group protein EZH2 in cancer.
    Cao Q; Yu J; Dhanasekaran SM; Kim JH; Mani RS; Tomlins SA; Mehra R; Laxman B; Cao X; Yu J; Kleer CG; Varambally S; Chinnaiyan AM
    Oncogene; 2008 Dec; 27(58):7274-84. PubMed ID: 18806826
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells.
    Fiskus W; Pranpat M; Balasis M; Herger B; Rao R; Chinnaiyan A; Atadja P; Bhalla K
    Mol Cancer Ther; 2006 Dec; 5(12):3096-104. PubMed ID: 17172412
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The transcriptional repressor NIPP1 is an essential player in EZH2-mediated gene silencing.
    Nuytten M; Beke L; Van Eynde A; Ceulemans H; Beullens M; Van Hummelen P; Fuks F; Bollen M
    Oncogene; 2008 Feb; 27(10):1449-60. PubMed ID: 17724462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27).
    McCabe MT; Graves AP; Ganji G; Diaz E; Halsey WS; Jiang Y; Smitheman KN; Ott HM; Pappalardi MB; Allen KE; Chen SB; Della Pietra A; Dul E; Hughes AM; Gilbert SA; Thrall SH; Tummino PJ; Kruger RG; Brandt M; Schwartz B; Creasy CL
    Proc Natl Acad Sci U S A; 2012 Feb; 109(8):2989-94. PubMed ID: 22323599
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combinatorial pharmacologic approaches target EZH2-mediated gene repression in breast cancer cells.
    Sun F; Chan E; Wu Z; Yang X; Marquez VE; Yu Q
    Mol Cancer Ther; 2009 Dec; 8(12):3191-202. PubMed ID: 19934278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EZH1 mediates methylation on histone H3 lysine 27 and complements EZH2 in maintaining stem cell identity and executing pluripotency.
    Shen X; Liu Y; Hsu YJ; Fujiwara Y; Kim J; Mao X; Yuan GC; Orkin SH
    Mol Cell; 2008 Nov; 32(4):491-502. PubMed ID: 19026780
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inner workings and regulatory inputs that control Polycomb repressive complex 2.
    O'Meara MM; Simon JA
    Chromosoma; 2012 Jun; 121(3):221-34. PubMed ID: 22349693
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polycomb protein EZH2 regulates tumor invasion via the transcriptional repression of the metastasis suppressor RKIP in breast and prostate cancer.
    Ren G; Baritaki S; Marathe H; Feng J; Park S; Beach S; Bazeley PS; Beshir AB; Fenteany G; Mehra R; Daignault S; Al-Mulla F; Keller E; Bonavida B; de la Serna I; Yeung KC
    Cancer Res; 2012 Jun; 72(12):3091-104. PubMed ID: 22505648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhancer of zeste homologue 2 (EZH2) down-regulates RUNX3 by increasing histone H3 methylation.
    Fujii S; Ito K; Ito Y; Ochiai A
    J Biol Chem; 2008 Jun; 283(25):17324-32. PubMed ID: 18430739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polycomb group protein-associated chromatin is reproduced in post-mitotic G1 phase and is required for S phase progression.
    Aoto T; Saitoh N; Sakamoto Y; Watanabe S; Nakao M
    J Biol Chem; 2008 Jul; 283(27):18905-15. PubMed ID: 18453536
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CDK1-dependent phosphorylation of EZH2 suppresses methylation of H3K27 and promotes osteogenic differentiation of human mesenchymal stem cells.
    Wei Y; Chen YH; Li LY; Lang J; Yeh SP; Shi B; Yang CC; Yang JY; Lin CY; Lai CC; Hung MC
    Nat Cell Biol; 2011 Jan; 13(1):87-94. PubMed ID: 21131960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epigenetic maintenance of stemness and malignancy in peripheral neuroectodermal tumors by EZH2.
    Burdach S; Plehm S; Unland R; Dirksen U; Borkhardt A; Staege MS; Müller-Tidow C; Richter GH
    Cell Cycle; 2009 Jul; 8(13):1991-6. PubMed ID: 19502792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting of EZH2 to a defined genomic site is sufficient for recruitment of Dnmt3a but not de novo DNA methylation.
    Rush M; Appanah R; Lee S; Lam LL; Goyal P; Lorincz MC
    Epigenetics; 2009 Aug; 4(6):404-14. PubMed ID: 19717977
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting EZH2 and PRC2 dependence as novel anticancer therapy.
    Xu B; Konze KD; Jin J; Wang GG
    Exp Hematol; 2015 Aug; 43(8):698-712. PubMed ID: 26027790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Noncanonical Functions of the Polycomb Group Protein EZH2 in Breast Cancer.
    Anwar T; Gonzalez ME; Kleer CG
    Am J Pathol; 2021 May; 191(5):774-783. PubMed ID: 33556366
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Signatures of polycomb repression and reduced H3K4 trimethylation are associated with p15INK4b DNA methylation in AML.
    Paul TA; Bies J; Small D; Wolff L
    Blood; 2010 Apr; 115(15):3098-108. PubMed ID: 20190193
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.